Valeant reports falling revenue for third consecutive quarter: 3 report insights

Laval, Canada-based Valeant Pharmaceuticals reported a 12.9 percent fall in its fourth quarter revenue, Reuters reports.

Here are three report insights.

1. Valeant's revenues fell 12.9 percent from $2.79 billion to $2.40 billion. The quarter is Valeant's third consecutive quarter of double-digit losses.

2. Valeant's net losses increased to $515 million in Q4.

3. Valeant has been attempting to "rebuild its business and regain investor confidence," after an investigation into its accounting and pricing methods, Reuters reports.

More articles on gastroenterology/endoscopy:
Comparing primary care to concierge core: Which is more costly?
Study: Physicians & NPs, PAs provide equal quality of care
Gainesville Endoscopy Center's new location to open its doors: 4 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months